ST. JOSEPH, Mo. (March 4, 2010) – Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the promotion of Cory Sullivan to associate director of Public Relations and Communications. Sullivan, who joined BIVI in June 2008, was associate director of Human Resources and Public Relations.
In her new role, Sullivan is responsible for the development and implementation of internal and external BIVI communications, including community outreach programs and employee communications activities for the company’s nearly 1,700 U.S. employees. In addition, she is responsible for all corporate media relations and serves as communications liaison with Boehringer Ingelheim USA in Ridgefield, Conn.
Previously, Sullivan was general director of human resources for Kansas City Southern Railway. She has an MBA from Rockhurst University, Kansas City, Mo., and a bachelor’s in journalism from the University of Central Oklahoma Edmond, Okla.
Dan Nowalk, executive director of Human Resources and Public Relations, says Sullivan’s experience with BIVI and communications background gives her a solid foundation for this new position. “Cory has proven time and again that she has the unique combination of communications and human resource management skills necessary to be successful in her new role,” Nowalk says. “She’s a tremendous asset to the company as we continue to grow our business and serve our customers.”
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit: www.bi-vetmedica.com
# # #
For More Information, Contact:
R. Kelly Schwalbe at 816-474-3166